Antibody Conjugates and Methods of Making and Using the Same
Antibodies that include a sulfatase motif-containing tag in a constant region of an immunoglobulin (Ig) light chain polypeptide are disclosed. The sulfatase motif can be converted by a formylglycine-generating enzyme (FGE) to produce a formylglycine (fGly)-modified Ig light chain polypeptide. An fGly-modified Ig light chain polypeptide of the antibody can be covalently and site-specifically bound to a moiety of interest to provide an antibody conjugate. The disclosure also encompasses methods of production of such tagged Ig light chain polypeptides, fGly-modified Ig light chain polypeptides, and antibody conjugates, as well as methods of use of same.
1 .- 41 . (canceled)
42 . An immunoglobulin (Ig) kappa light chain polypeptide comprising, in a constant region, an amino acid sequence selected from:
i) SEQ ID NO: 6, SEQ ID NO: 16, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 40, and SEQ ID NO: 42; or
ii) a sequence having, exclusive of the sequence LCTPSR (SEQ ID NO: 158), at least 90% sequence identity to a sequence from entry (i);
wherein the cysteine residue in the sequence LCTPSR (SEQ ID NO: 158) is oxidized to fGly.
43 . The Ig kappa light chain polypeptide of claim 42 , wherein the fGly is covalently bound to a payload.
44 . The Ig kappa light chain polypeptide of claim 43 , wherein the fGly is covalently bound to the payload via a hydrazone, oxime, semicarbazone, alkyl, alkenyl, acyloxy, hydrazinyl-indolyl, hydrazinyl-imidazoyl, hydrazinyl-pyrrolyl, hydrazinyl-furanyl or a pyrazolinone linkage.
45 . The Ig kappa light chain polypeptide of claim 43 , wherein the fGly is covalently bound to the payload via a linking group.
46 . The Ig kappa light chain polypeptide of claim 45 , wherein the linking group comprises a 4-aminopiperidine derivative (4AP).
47 . The Ig kappa light chain polypeptide of claim 43 , wherein the payload is a drug, a detectable label, a water-soluble polymer, a viral fusion inhibitor, or a synthetic peptide.
48 . The Ig kappa light chain polypeptide of claim 47 , wherein the drug is a small molecule drug.
49 . The Ig kappa light chain polypeptide of claim 48 , wherein the small molecule drug is a cancer chemotherapeutic agent.
50 . The Ig kappa light chain polypeptide of claim 49 , wherein the cancer chemotherapeutic agent is an alkylating agent, a nitrosourea, an antimetabolite, an antitumor antibiotic, a vinca alkaloid, or a steroid hormone.
51 . The Ig kappa light chain polypeptide of claim 47 , wherein the water-soluble polymer is poly(ethylene glycol).
52 . The Ig kappa light chain polypeptide of claim 47 , wherein the detectable label is an imaging agent.
53 . A recombinant nucleic acid comprising a nucleotide sequence encoding the Ig kappa light chain polypeptide of claim 42 .
54 . A recombinant expression vector comprising the nucleic acid of claim 53 , wherein the nucleotide sequence encoding the Ig kappa light chain polypeptide is operably linked to a promoter.
55 . A host cell genetically modified to express the Ig kappa light chain polypeptide of claim 42 .
56 . The host cell of claim 55 , genetically modified to express a formylglycine generating enzyme (FGE), in a manner sufficient to convert the Ig kappa light chain polypeptide into an fGly-modified Ig kappa light chain polypeptide.
57 . The host cell of claim 56 , wherein the host cell is a mammalian cell.
58 . An antibody comprising the Ig kappa light chain polypeptide of claim 42 .
59 . The antibody of claim 58 , wherein the antibody specifically binds a tumor antigen on a cancer cell.
60 . A formulation comprising: the antibody of claim 59 and a pharmaceutically acceptable excipient.
61 . An immunoglobulin (Ig) kappa light chain polypeptide comprising, in a constant region, an amino acid sequence selected from the group consisting of: i) SEQ ID NO: 6, SEQ ID NO: 16, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 40, and SEQ ID NO: 42,
wherein the cysteine residue in the sequence LCTPSR (SEQ ID NO: 158) is oxidized to fGly.